A transfusion order is usually based on a laboratory result, such as a hemoglobin, platelet count, INR, or fibrinogen. A transfusion is justified by a laboratory result in clinical context, an expected response from a specific component, and a plan for special processing or emergency support. The laboratory contributes the counts, coagulation results, compatibility record, and response measurements needed to assess whether the component produced its expected effect. Blood Product Processing, Storage, Components, and Quality Control covers component manufacture, storage conditions, labeling, and product quality control. This lesson covers component selection and dose.
Expected response per component
Each component has an expected average effect in a typical adult, and the laboratory verifies that response with posttransfusion counts.1
Scroll sideways to see all columns
| Component | Major indication | Expected effect in a 70 kg adult |
|---|---|---|
| Whole Blood | Large-volume hemorrhage needing red-cell mass, plasma volume, and nonlabile factors together | 1 unit raises hemoglobin about 1 g/dL (hematocrit about 3 percentage points) |
| Red cells | Symptomatic anemia or inadequate oxygen-carrying capacity | 1 unit raises hemoglobin about 1 g/dL |
| Apheresis platelets | Bleeding or prophylaxis in thrombocytopenia or platelet dysfunction | 1 unit (at least 3.0 × 1011 platelets) raises the count about 30,000 to 60,000/µL |
| Whole-blood-derived platelets | Same, when pooled | 1 unit (at least 5.5 × 1010 platelets) raises the count of a 70 kg adult about 5,000 to 10,000/µL |
| Granulocytes | Neutropenia below 500/µL with infection unresponsive to antimicrobials and expected marrow recovery | Given within 24 hours of collection; the red-cell content requires ABO compatibility and a serologic crossmatch |
| Plasma | Multiple coagulation factor deficiency without a safer specific product | Dosed by volume, commonly about 15 mL/kg, then reassessed clinically and by coagulation testing |
| Cryoprecipitate | Fibrinogen deficiency or factor XIII deficiency without a preferred concentrate | 1 unit provides at least 150 mg fibrinogen and 80 IU factor VIII |
AABB Circular Table 3 gives suggested pediatric doses for patients weighing less than 50 kg. It lists CPD or CPDA-1 red cells at 5 to 15 mL/kg with an expected hemoglobin rise of about 3 g/dL, and additive-solution red cells at 10 to 15 mL/kg with an expected rise of about 2 g/dL. Plasma at 10 to 15 mL/kg raises most factor levels about 15 to 20 percent, and cryoprecipitate at 1 to 2 units per 10 kg raises fibrinogen about 60 to 100 mg/dL under the assumed ideal recovery.1 Red-cell increments are estimates. They depend on component hematocrit, administered volume, recipient blood volume, and ongoing blood loss, so a dose within the range may produce a smaller rise than listed.
The per-unit red-cell increment depends on blood volume. One red-cell unit contributes roughly 200 mL of red cells. For a 90 kg adult with an estimated blood volume of 6,300 mL (90 kg × 70 mL/kg) and a hematocrit of 24%, the red-cell mass is 6,300 × 0.24 = 1,512 mL. Adding 200 mL gives 1,712 mL, and after volume equilibration the estimated hematocrit is 1,712 ÷ 6,300 = 27.2%, a rise of about 3.2 percentage points. The same arithmetic for a 70 kg adult, with a blood volume of 4,900 mL and the same 24% hematocrit, gives a red-cell mass of 4,900 × 0.24 = 1,176 mL and (1,176 + 200) ÷ 4,900 = 28.1%, a rise of about 4.1 percentage points. The blood-volume model therefore predicts a larger rise in the smaller patient. At average weight, the model predicts a larger rise than the bedside rule of about 1 g/dL hemoglobin, or roughly 3 hematocrit points, per unit. The bedside rule already accounts for incomplete recovery of transfused red cells.2
Platelet response is measured with the corrected count increment (the platelet rise corrected for dose and recipient size) when repeated increments are lower than expected. The formula, its 10-to-60-minute assessment window, and the interpretation of immune and nonimmune refractoriness are covered in the Leukocyte and Platelet Antigen Testing lesson. ABO-identical platelets give the best increments. Group O recipients respond less well to group A platelets, and repeated ABO-incompatible platelet transfusion can produce a positive direct antiglobulin test from passively transferred anti-A or anti-B.2
Red cell thresholds
For most hospitalized, hemodynamically stable adults, the 2023 AABB international guideline recommends a restrictive red-cell transfusion strategy that considers transfusion when hemoglobin is below 7 g/dL (strong recommendation, moderate-certainty evidence). Symptoms, comorbidity, the rate of hemoglobin decline, bleeding, and hemodynamic status determine whether a result below that value warrants transfusion.3
Hospitalized adults with acute myocardial infarction are a defined exception. A 2025 AABB international guideline suggests a liberal strategy for these patients when hemoglobin is below 10 g/dL, a conditional recommendation based on low-certainty evidence that a restrictive strategy of 7 to 8 g/dL may increase mortality in these patients.4
Red cells are indicated for symptomatic or critical deficit of oxygen-carrying capacity and for red-cell exchange. Red cells are not indicated for anemia that specific hematinics such as iron, vitamin B12, folate, or erythropoietin can correct. Red-cell-containing components are also not indicated for volume expansion or oncotic support alone.1
Platelet support
Prophylactic platelet thresholds are population-specific. For nonbleeding patients with hypoproliferative thrombocytopenia who are receiving chemotherapy or undergoing allogeneic hematopoietic stem-cell transplantation, the 2025 AABB and ICTMG guideline recommends prophylactic platelet transfusion at counts below 10,000/µL. For nonbleeding adults with hypoproliferative thrombocytopenia undergoing autologous transplantation or with aplastic anemia, the same guideline suggests against routine prophylaxis, a conditional recommendation. Other populations have separate recommendations, and the treating clinician makes the transfusion decision.13 Thrombocytopenia is unlikely to be the sole cause of bleeding at counts of 50,000/µL or above. The Circular notes that higher thresholds may be appropriate for central nervous system bleeding and platelet-function defects. It lists heparin-induced thrombocytopenia, thrombotic thrombocytopenic purpura, and immune thrombocytopenic purpura as disorders in which platelets are not used unless the patient has a life-threatening hemorrhage, because platelet activation or immune destruction is the underlying process.1
Platelets express ABO antigens and lack Rh antigens. Residual red cells in the component can expose a D-negative recipient to D. The alloimmunization risk is higher with whole-blood-derived platelets and very low with apheresis platelets. For a D-negative female of childbearing potential who receives D-positive platelets, Rh immune globulin can be considered to prevent D alloimmunization, dosed from the estimated residual D-positive red-cell volume under the validated product and facility protocol.1,5
Plasma and cryoprecipitate
Plasma replaces multiple coagulation factors at once. The current Circular of Information indicates plasma for preoperative or bleeding patients who need multiple factors, such as liver disease or disseminated intravascular coagulation; massive transfusion with clinically significant factor deficiency; urgent warfarin reversal when vitamin K cannot act in time; plasma exchange in thrombotic thrombocytopenic purpura; and factor deficiencies for which no concentrate is available. Plasma must be ABO compatible with the recipient's red cells, and D compatibility is not required. A standard dose of about 15 mL/kg may leave a minimally elevated INR unchanged. An INR of 1.7 or less reflects at least 30% factor activity, which supports normal hemostasis. The Circular therefore lists plasma transfusion to correct a minimally elevated INR of 1.7 or less as a relative contraindication.1
Cryoprecipitate supplies fibrinogen, factor VIII, factor XIII, and von Willebrand factor in concentrated form. Factor concentrates are preferred for von Willebrand disease, hemophilia A, and factor XIII deficiency, so cryoprecipitate is reserved for fibrinogen deficiency, second-line use in those disorders, and selected uremic bleeding after other measures fail.1
Plasma derivatives and factor concentrates
Plasma derivatives are manufactured from large plasma pools with product-specific viral inactivation, so their infection risk profile differs from that of single-donor components.
Factor-concentrate response. Factor concentrate potency is labeled in International Units, and expected recovery is product-specific. The current ADVATE label estimates a peak factor VIII increment by dividing the administered units by body weight and multiplying by 2 IU/dL per IU/kg. Under that label, 1,276 IU administered to a 70 kg patient predicts an increment of about 36.5 IU/dL. Serial factor VIII activity establishes the observed recovery because individual pharmacokinetics vary. Factor IX recovery and monitoring also follow the specific product label and the measured factor IX activity. The clinical service selects the concentrate, target, and dose. The laboratory measures the response and investigates an inhibitor when recovery is lower than expected.6
Albumin. Albumin is supplied at several concentrations and is used as an apheresis replacement fluid under the procedure order. The FLEXBUMIN 25% label states that it is osmotically equivalent to approximately five times its volume of human plasma and, when the patient is not markedly dehydrated, draws about 3.5 times its volume of additional fluid into the circulation within 15 minutes. The first figure describes oncotic equivalence, and the second describes early volume expansion.7
Immune globulin. Route is product-specific. GAMASTAN is an intramuscular immune globulin whose label states that it must not be administered intravenously because serious reactions can occur. Products labeled as intravenous immune globulin are different preparations. Read the supplied product's label for the route and handling.8
Rh immune globulin. Rh immune globulin supplies passive anti-D to prevent D alloimmunization in an eligible unsensitized patient. Proposed mechanisms include removal of D-positive cells and suppression of D-specific B-cell activation. One 300 µg dose covers 15 mL of D-positive red cells or 30 mL of D-positive whole blood, and the calculated dose for a large exposure is rounded up to the next whole dose. The antenatal and postpartum dosing pathway, fetomaternal hemorrhage quantification, and passive-versus-immune anti-D interpretation are covered in the Hemolytic Disease of the Fetus and Newborn lesson.5,9
Special processing requirements
Four component modifications have specific clinical indications. The processing and dating consequences of each modification are covered in the processing lesson.
Leukoreduction removes donor leukocytes to fewer than 5 × 106 per unit for red cells, apheresis platelets, and pooled platelets, and fewer than 8.3 × 105 for a single whole-blood-derived platelet. Prestorage filtration is preferred because bedside filtration lacks routine quality control and can cause severe hypotension in recipients taking angiotensin-converting enzyme inhibitors. Leukoreduced components reduce recurrent febrile nonhemolytic reactions, reduce HLA alloimmunization, and reduce cytomegalovirus transmission risk. Their effects on hospital length of stay and postoperative infection are not established.1
Washing and freezing have specific indications. Washing removes residual plasma proteins and is indicated for recurrent severe allergic reactions and for IgA-deficient patients with anti-IgA, and washing removes the glycerol from thawed frozen red cells. Frozen storage preserves rare-phenotype units for as long as 10 years, and a deglycerolized unit expires 24 hours after thawing in an open system, with up to 14 days permitted in an approved closed system. The processing steps and quality-control specifications are covered in the processing lesson.1,2
Cytomegalovirus (CMV) risk reduction applies to seronegative recipients at risk of severe primary infection: pregnant women and their fetuses, low-birth-weight infants, hematopoietic progenitor cell and solid-organ transplant recipients, severely immunosuppressed recipients, and patients with HIV infection. CMV persists latently in mononuclear leukocytes, so prestorage leukoreduction or CMV-seronegative selection reduces transmission risk to comparable low levels. Plasma and cryoprecipitate have no meaningful CMV transmission risk.1
Irradiation prevents transfusion-associated graft-versus-host disease by rendering donor T lymphocytes incapable of proliferation. The standard dose is 2,500 cGy targeted to the central portion of the container with at least 1,500 cGy to every part of the component.1 Three conditions must coexist for disease: viable donor T lymphocytes in the component, an HLA disparity in the direction the donor cells can attack, and a recipient unable to reject them. Irradiation is indicated for intrauterine transfusion recipients, selected neonatal and immunocompromised recipients, cellular components from blood relatives, hematopoietic progenitor cell transplant recipients, HLA-selected components, and granulocytes, which always require irradiation. Purine analogue therapy and immunomodulators such as alemtuzumab or antithymocyte globulin create risk that depends on clinical factors, and Hodgkin lymphoma and purine analogue therapy are common additional indications. A crossmatch-compatible platelet unit requires irradiation when it is also HLA selected, when another indication applies, or when facility policy requires it. Irradiation is not universally required for solid-organ transplantation, acute leukemia, or low birth weight. The requirement depends on the diagnosis, treatment regimen, timing, and facility policy, and the duration after transplant is program-specific.1
Emergency and massive transfusion
Emergency release follows the facility procedure described in the Pretransfusion Testing lesson: the pretransfusion specimen is collected first whenever feasible, group O red cells or low-titer group O whole blood is used for a patient whose group is unknown, under the medical-director-approved D-allocation policy, and ABO, D, and antibody testing continues in parallel. Low-titer cutoffs are facility-defined because no universal safe titer exists.1,2
Massive transfusion means replacement of one blood volume within 24 hours, roughly 10 adult red cell units, or half a blood volume within 3 hours. The facility protocol defines activation, emergency release, and the initial component packs. Serial platelet count, PT or INR, activated partial thromboplastin time (APTT), fibrinogen, blood gas, ionized calcium, and viscoelastic (thromboelastography or rotational thromboelastometry) results then guide component issue and critical communication.2
Scroll sideways to see all columns
| Laboratory finding during massive transfusion | Component response |
|---|---|
| Platelet count below 50,000/µL | Platelets |
| PT ratio or INR above 1.5, or APTT above 60 seconds | Plasma |
| Fibrinogen below the protocol trigger, which differs between trauma and obstetric protocols | Cryoprecipitate or fibrinogen concentrate |
Large-volume transfusion has predictable metabolic effects. Hypothermia from refrigerated blood worsens coagulopathy, and each 4 °C unit can lower core temperature by about 0.25 °C in an average adult. Citrate from the anticoagulant chelates ionized calcium. When citrate is infused faster than the liver can metabolize it, perioral tingling, tetany, hyperventilation, and arrhythmia can occur, with the greatest risk in liver failure and circulatory collapse. Measure ionized calcium, because total calcium does not reflect this change. Potassium released during storage causes transient hyperkalemia that is most significant in neonates and in renal, hepatic, or cardiac dysfunction. Dilutional coagulopathy develops as crystalloid and red-cell resuscitation proceeds without proportional plasma and platelets. Platelet counts below 50,000/µL and factor levels near 25% are typical after roughly two blood-volume replacements.1,2
Neonatal transfusion
Small-aliquot red-cell transfusion replaces phlebotomy losses and treats anemia of prematurity. Component age and aliquot selection follow the neonatal transfusion procedure. A randomized trial in premature, very low-birth-weight infants found no improvement in its clinical outcomes with red cells stored 7 days or less compared with standard practice. Mean storage ages were 5.1 and 14.6 days. That finding does not establish equivalence for every storage duration or for exchange or intrauterine transfusions.10 CMV-risk reduction and irradiation follow the requirements above. Irradiation is required for an intrauterine transfusion and for subsequent neonatal transfusions after an intrauterine transfusion. For exchange transfusion and for low birth weight alone, the irradiation and CMV requirements follow the current jurisdictional guideline and facility policy. Red cells for intrauterine, exchange, and other large-volume neonatal transfusions, and for known or suspected sickle cell disease, should be Hb S-negative, and urgent small-volume support proceeds under policy when such a unit is unavailable.1,11
Oncology and chronically transfused patients
Repeated red-cell and platelet transfusion makes compatibility testing progressively more difficult. Red-cell alloimmunization makes compatible units harder to find and increases the risk of delayed hemolytic transfusion reactions, and platelet refractoriness may require HLA-matched or crossmatch-compatible apheresis platelets as evaluated in the Leukocyte and Platelet Antigen Testing lesson. Chronic transfusion also adds roughly 250 mg of iron per unit, with significant accumulation possible after 10 to 20 transfusions. Serial ferritin measurements monitor the iron load.1 Hematologic malignancies such as chronic lymphocytic leukemia and lymphoma are frequently associated with autoimmune hemolytic anemia, which complicates compatibility testing through the mechanisms described in the Warm, Mixed, and Drug-Induced Immune Hemolytic Anemia lesson.
Laboratory support for coagulation deficiencies
Factor VIII activity supports hemophilia A evaluation, and factor IX activity supports hemophilia B evaluation. Mixing studies and inhibitor assays investigate an unexpectedly low factor level or poor postinfusion recovery. In von Willebrand disease, von Willebrand factor antigen, activity, factor VIII, and selected multimer or platelet-binding studies distinguish quantitative deficiency from type 2 variants. Type 2B has increased platelet binding and loss of high-molecular-weight multimers, a distinction the laboratory reports because it affects the clinical plan.12
PT or INR patterns help separate vitamin K deficiency or warfarin effect from broader factor deficiency. Serial PT, APTT, fibrinogen, D-dimer, and platelet results monitor disseminated intravascular coagulation and guide component support under the facility protocol. Platelet function testing, medication history, and the renal profile help distinguish a drug effect, uremia, and a congenital defect. The clinical service selects reversal, medication changes, and other treatment. The transfusion service supplies ordered components according to the laboratory pattern and compatibility requirements.1,2
Surgical blood ordering
Most surgical procedures need no transfusion. A maximum surgical blood order schedule lists the maximum red-cell units to crossmatch for each procedure or specifies type-and-screen only. The schedule is based on the facility's own procedure-specific transfusion experience. Together with a type-and-screen policy, it targets a crossmatch-to-transfusion ratio of 2:1 to 3:1 and preserves inventory and testing time for patients with antibodies. When a scheduled patient has antibodies, start the compatible-unit search early, using the testing time that the schedule saves.2
References
- Association for the Advancement of Blood & Biotherapies, American Red Cross, America's Blood Centers, Armed Services Blood Program. Circular of Information for the Use of Human Blood and Blood Components. June 2024. Accessed August 31, 2026. Back to text
- Bloch EM, Campbell-Lee S, McKenna DH Jr, Montemayor-Garcia C, Schwartz J, Shaz B, Storry J, eds. Technical Manual. 22nd ed. AABB; 2026. Back to text
- Carson JL, Stanworth SJ, Guyatt G, et al. Red blood cell transfusion: 2023 AABB international guidelines. JAMA. 2023;330(19):1892-1902. doi:10.1001/jama.2023.12914 Back to text
- Pagano MB, Stanworth SJ, Dennis J, et al. Red cell transfusion in acute myocardial infarction: AABB international clinical practice guidelines. Ann Intern Med. 2025;178(10):1469-1477. doi:10.7326/ANNALS-25-00706 Back to text
- AABB. Association Bulletin #24-02: Use of Rh Immune Globulin and Considerations in the Setting of Supply Shortages and Limited Availability. July 15, 2024. Accessed August 31, 2026. Back to text
- Takeda Pharmaceuticals USA Inc. ADVATE [antihemophilic factor (recombinant)] prescribing information. DailyMed. Accessed August 31, 2026. Back to text
- Takeda Pharmaceuticals USA Inc. FLEXBUMIN 25% [albumin human] prescribing information. DailyMed. Revised December 2024. Accessed August 31, 2026. Back to text
- Grifols USA LLC. GAMASTAN [immune globulin (human)] prescribing information. DailyMed. Revised August 2022. Accessed August 31, 2026. Back to text
- Kedrion Biopharma Inc. RhoGAM Ultra-Filtered PLUS and MICRhoGAM Ultra-Filtered PLUS [prescribing information]. Revised July 2025. Accessed August 31, 2026. Back to text
- Fergusson DA, Hébert P, Hogan DL, et al. Effect of fresh red blood cell transfusions on clinical outcomes in premature, very low-birth-weight infants: the ARIPI randomized trial. JAMA. 2012;308(14):1443-1451. doi:10.1001/2012.jama.11953 Back to text
- Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020;4(2):327-355. doi:10.1182/bloodadvances.2019001143 Back to text
- Connell NT, Flood VH, Brignardello-Petersen R, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv. 2021;5(1):301-325. doi:10.1182/bloodadvances.2020003264 Back to text
- Metcalf RA, Cohn CS, Bakhtary S, et al. Platelet transfusion: 2025 AABB and ICTMG international clinical practice guidelines. JAMA. 2025. doi:10.1001/jama.2025.7529 Back to text